Dr Katie Chapman is a Assay biologist and currently leads the assay biology group at Domainex. Previously she was a member of the Drug Discovery Centre and Head of the Mechanism and Functional Screening Facility at Imperial College London. Prior to this she worked at GlaxoSmithKline as a Senior Scientist in the Screening and Compound Profiling Department. Here she was responsible for the biochemical kinase assay portfolio ensuring the weekly delivery of over 20 kinase assay data sets for over 5 different projects worldwide across the company.
Further to this she has worked on a number of different hit identification kinase projects which include; Identification of CDPK inhibitors as anti-malaria therapeutic in collaboration with Imperial College, Sanger Centre and GSK Open Lab Foundation. Finally, at Domainex she is currently the Project Leader for the lead optimisation of MAP4K4 inhibitors for use in cardioprotection, funded by Wellcome Trust SDD grant scheme and in collaboration with Professor Michael Schneider at Imperial College.
Wednesday, February 7
1:30 PM – 2:00 PM